相关实验视频
Updated: Jul 14, 2025

10:43
Evaluating In Vitro DNA Damage Using Comet Assay
Published on: October 11, 2017
37.7K
奥拉巴里布和美特福林之间的双向药物相互作用
Joanna Stanisławiak-Rudowicz1,2, Agnieszka Karbownik3, Danuta Szkutnik-Fiedler3
1Department of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, Rokietnicka 3, 60-806, Poznań, Poland. jstanislawiak@ump.edu.pl.
Cancer chemotherapy and pharmacology
|October 10, 2023
概括
甲胺不会改变olaparib的药理学. 然而,olaparib显著增加了甲胺水平,这表明对服用这两种药物的患者具有潜在的临床重要性.
科学领域:
- 药理学和药物新陈代谢
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
背景情况:
- 奥拉巴里布是一种PARP抑制剂,用于治疗BRCA突变癌症.
- 甲胺是2型糖尿病的主要治疗方法.
- 在患有糖尿病的癌症患者中,Olaparib和美特福林的同时使用.
研究的目的:
- 为了研究olaparib和metformin之间的药理学相互作用.
- 为了确定甲福明是否会影响olaparib的药理动力学 (PK).
- 评估olaparib对甲福林的PK参数的影响.
主要方法:
- 一个单剂量研究在Wistar大鼠.
- 甲福明,奥拉巴里布或两者的口服.
- 使用HPLC测量药物度的血液样本分析.
- 非分区分析用于计算PK参数,如AUC (曲线下的面积).
主要成果:
- 甲福明并没有显著改变olaparib的PK参数 (AUC比:0.99).
- 奥拉巴里显著增加了甲胺的Cmax (177.8%),AUC0-t (159.8%),以及AUC0-∞ (74.1%).
- 在olaparib的存在下,甲福明的AUC比率为1.74.
结论:
- 单剂量甲胺不影响olaparib PK或新陈代谢.
- 奥拉巴里布显著改变了美特福林的药理动力学.
- 这些发现突出了olaparib和metformin联合使用的潜在临床影响.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
173
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
173
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
185
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
185
Dipeptidyl Peptidase 4 Inhibitors
192
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
192
Factors Affecting Protein-Drug Binding: Drug Interactions
173
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
173
Drug Metabolism: Phase II Reactions
3.9K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.9K

